Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
about
Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and PhosphorylationHumanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyStabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau passive immunization inhibits not only tau but also Aβ pathologyTau Immunotherapy.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approachTau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.Tauopathies: Mechanisms and Therapeutic Strategies.Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice."Tau immunotherapy: Hopes and hindrances".Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein.A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.
P2860
Q26748105-F7EF9DED-23E6-42A7-853E-F0C97A1FE571Q33640390-01345C90-0527-46C6-BD30-3472F5C1F05BQ35972860-1827C024-6C57-4C03-A848-49F6F481E840Q36484413-50CF5667-3061-4C60-8E85-89A76C5F5E7BQ37579019-54C1342D-A5B4-4C29-8CA0-593586FDC1E8Q38628672-C23A08BD-997C-49CC-AA1C-A7098BD7812CQ41629521-FAB5ECCB-70FC-4F32-B121-E6E308BC0064Q46383545-D33C491E-6C92-496C-BE5E-5D7D86E9EE81Q47253592-F22D9F72-1E45-4BE5-A4F1-5227528B8289Q47547728-7A926BC7-9F41-4AB5-92E0-E78C7567F251Q47629452-2323E60A-978A-4756-8BAF-DA5CCD9C6CF5Q50045202-55941520-F58D-4F3F-B78B-7EE5F8022C37Q50525085-A7062A56-BB65-42F9-85F1-E0E7C118CCADQ55118610-99143EDF-E67A-4142-9758-7211640D7CCBQ55238549-F4E80718-CD3F-483C-85A6-A3A5D1571764
P2860
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@ast
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@en
type
label
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@ast
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@en
prefLabel
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@ast
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@en
P2093
P2860
P356
P1476
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
@en
P2093
Hiroshi Eguchi
Hiroshi Mori
Taizo Taniguchi
Takami Tomiyama
Tomohiro Umeda
Yoichi Matsumoto
Yuichi Kunori
P2860
P304
P356
10.1002/ACN3.171
P577
2015-01-09T00:00:00Z